Trial Search Results

Adiponectin Polymorphisms, Insulin Resistance, and Pharmacokinetics in Obesity

The primary objective of this study is to determine the influence of insulin resistance on drug metabolism and response in obese subjects. The investigators hypothesize that expression of adiponectin (a hormone secreted by fat tissue), and specific variants in the adiponectin gene can predict the insulin resistance and drug response among obese subjects.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: National Institute of General Medical Sciences (NIGMS)

Stanford Investigator(s):


  • Drug: Propofol and Fentanyl administration


Phase 1


Inclusion Criteria:

   - Inclusion criteria include patients of adult age

   - American Society of Anesthesiologists Class I, II, or III, and undergoing elective
   surgical procedures requiring general anesthesia

   - Body mass index greater than 35

Exclusion Criteria:

   - Patients with evidence of hepatic, renal, or cardiovascular dysfunction

   - History of difficult tracheal intubation, or adverse reaction to anesthesia shall be
   excluded from the study

   - Patients taking prescribed or over-the-counter anxiolytics, narcotics, or sleeping
   aids, will also be excluded

Ages Eligible for Study

18 Years - 70 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jerry Ingrande, M.D., M.S.